Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesIs screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study
Journal of Rheumatology, 07/02/09
Guennoc X et al. - Prevalence of hepatitis B (HBV) and C (HCV) in a population of patients with recent-onset polyarthritis was not greater than the general population in France. Routine HBV and HCV serological testing did not contribute to the diagnosis of RA, however serological testing before initiating immunosuppressive or hepatotoxic drugs is advisable.
Methods- An evaluation of seroprevalence of HBV and HCV in pts living in France with recent-onset polyarthritis suggesting RA
- 813 pts in ESPOIR cohort were screened for anti-HCV antibodies and HBs antigen
- Seroprevalence was 0.86% for HCV and 0.12% for HBV
- HCV-related arthritis was diagnosed in 0.5% pts; no patient had HBV-related arthritis
- HCV-seropositive pts had higher transaminase levels but only 2 pts had ASAT or ALAT levels >40 IU
- No difference for anti-CCP Abs, CRP, ESR, or other test
- HCV seroprevalence was higher in subgroup with history of blood transfusion vs other pts
- 2/7 HCV positive pts and single patient with confirmed hepatitis B infection were born in areas with higher prevalence of viral hepatitis
- Positive hepatitis status was known before study inclusion in 4/7 HCV-positive pts and in HBV-positive patient
Today in Other Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/26/09
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Annals of Rheumatic Diseases, 10/12/09
The beneficial effects of a 3 week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: Results of the STIVEA trial
Annals of Rheumatic Diseases, 10/23/09
Sponsor
Article Search
Sponsor